search
Back to results

Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder

Primary Purpose

Overactive Bladder, Overactive Bladder Syndrome

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Oral Solifenacin 5mg
Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)
Sponsored by
Ege University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder focused on measuring Overactive Bladder, Transcutaneous Electric Nerve Stimulation, Neuromodulation, Urge Urinary Incontinence, Quality of Life

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female patients with a diagnosis of OAB and unresponsive to first-line treatment, Absence of genito-urinary system malformations that may cause pollacullaire, Volunteering to participate in the research, To be literate in Turkish Exclusion Criteria: Having a urinary tract infection, Having pelvic organ prolapse greater than stage 2, To be diagnosed with stress type urinary incontinence, Having narrow-angle glaucoma, myasthenia gravis and severe gastro-intestinal diseases, Patients undergoing hemodialysis, Having severe liver or kidney failure, Pregnancy, Having a pacemaker Presence of epilepsy, The presence of built-in metal in the ankle Open ankle wound

Sites / Locations

  • Ege University, School of Medicine, Department of Obstetrics and Gynecology

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Device Group

Drug Group

Arm Description

Transcutaneous device group with Urostim 2

Drug Group with Kinzy 5 mg

Outcomes

Primary Outcome Measures

Number of Total Daily Incontinence Episodes
It was obtained using a three-day bladder diary. Objective. Meaningful for patients. Correlates with patients' daily activities. It may not be directly related to the severity of urine leakage. Subject to variability. Requires patient compliance. Day and night urine leakages were recorded separately by the patient for three days. The mean total score for a day was calculated.
Evaluation of Quality of Life
The Incontinence Quality of Life Scale (I-QOL), consisting of 22 questions, was used to analyze the improvement in quality of life. It is a validated questionnaire. Higher scores indicate a better level of quality of life compared to lower scores. It is meaningful for patients. It is standardized. It takes into account the patient's daily activities. Subjective. Subject to variability. Not correlated with the severity of urine leakage.

Secondary Outcome Measures

Symptom Assessment
Overactive Bladder Assessment Form (OAB-V8), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A higher score means a worse outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Symptom Assessment
Urogenital Distress Inventory (UDI-6), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A lesser score means a better outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Symptom Assessment
Incontinence Impact Questionnaire (IIQ-7), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A lesser score means a better outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.

Full Information

First Posted
July 2, 2023
Last Updated
September 4, 2023
Sponsor
Ege University
search

1. Study Identification

Unique Protocol Identification Number
NCT06024005
Brief Title
Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder
Official Title
A Prospective Randomized Controlled Trial: Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Oral Solifenacin Treatments' Effects in Women Between 18-80 Years Old Who Have Overactive Bladder
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
April 18, 2023 (Actual)
Primary Completion Date
May 24, 2023 (Actual)
Study Completion Date
May 24, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ege University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Overactive bladder (OAB) syndrome is a symptom complex characterized by sudden urgency, frequent urination, nocturia, and urge incontinence without any identifiable organic cause, significantly impacting the quality of life. One of the most prominent symptoms is the urgency to urinate accompanied by a sudden sensation of bladder fullness. There are various treatment options available for managing OAB, including conservative therapy, pharmacotherapy, and surgical management. High-level evidence supports solifenacin as the standard medical treatment for OAB, offering advantages such as not being affected by food intake, efficacy regardless of gender, and high bioavailability. However, it is known to cause discontinuation of treatment in many cases due to the occurrence of side effects. Posterior tibial nerve stimulation (PTNS) is a neuromodulation technique that has been internationally recognized and proven effective in the treatment of OAB, providing several advantages. It can be applied through two methods: percutaneous (PTNS) and transcutaneous (TTNS). PTNS is an invasive method that requires specialized equipment and a trained healthcare professional, which limits its routine use due to treatment costs. In the literature, it is stated that in the treatment of OAB, alone or combined PTNS applications are superior to drug monotherapies, but there are limited studies on this subject. Therefore, the study aim was to compare the efficacy, side effects and quality of life of solifenacin and TTNS.
Detailed Description
According to the inclusion and exclusion criteria, 34 female patients with OAB were enrolled in the study. The patients were randomly divided into two groups, with 17 individuals in each group. Patients with odd case numbers were assigned to the Oral Solifenacin group, while those with even case numbers were assigned to the TTNS group. Prior to treatment, the sociodemographic characteristics, birth history, and past treatment information of all participants were recorded. Basic urogynecological evaluation, pelvic floor ultrasound, and urine culture were performed. To assess symptoms and quality of life, the Overactive Bladder Assessment Form (OAB-V8), Incontinence Quality of Life Scale (I-QQL), Incontinence Impact Questionnaire (IIQ-7), Urogenital Distress Inventory (UDI-6), and a three-day bladder diary were used. After 6 weeks of treatment, all evaluations were repeated. The treatment regimen consisted of once-daily oral solifenacin for the medication group and 2 sessions per week, 30 minutes per session, for 12 sessions using the Urostim-2 device for the TTNS group. The stimulation intensity was increased until a motor or sensory response was obtained, and the threshold value was determined. The entire TTNS procedure was performed under the supervision of an expert physician at the Urogynecology Outpatient Clinic of Ege University Hospital. Statistical analysis was conducted using SPSS 20.0.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder, Overactive Bladder Syndrome
Keywords
Overactive Bladder, Transcutaneous Electric Nerve Stimulation, Neuromodulation, Urge Urinary Incontinence, Quality of Life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Device Group
Arm Type
Active Comparator
Arm Description
Transcutaneous device group with Urostim 2
Arm Title
Drug Group
Arm Type
Active Comparator
Arm Description
Drug Group with Kinzy 5 mg
Intervention Type
Drug
Intervention Name(s)
Oral Solifenacin 5mg
Other Intervention Name(s)
Kinzy 5mg
Intervention Description
Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
Intervention Type
Device
Intervention Name(s)
Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)
Other Intervention Name(s)
Urostim 2
Intervention Description
Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
Primary Outcome Measure Information:
Title
Number of Total Daily Incontinence Episodes
Description
It was obtained using a three-day bladder diary. Objective. Meaningful for patients. Correlates with patients' daily activities. It may not be directly related to the severity of urine leakage. Subject to variability. Requires patient compliance. Day and night urine leakages were recorded separately by the patient for three days. The mean total score for a day was calculated.
Time Frame
6 weeks
Title
Evaluation of Quality of Life
Description
The Incontinence Quality of Life Scale (I-QOL), consisting of 22 questions, was used to analyze the improvement in quality of life. It is a validated questionnaire. Higher scores indicate a better level of quality of life compared to lower scores. It is meaningful for patients. It is standardized. It takes into account the patient's daily activities. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Symptom Assessment
Description
Overactive Bladder Assessment Form (OAB-V8), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A higher score means a worse outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Time Frame
6 weeks
Title
Symptom Assessment
Description
Urogenital Distress Inventory (UDI-6), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A lesser score means a better outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Time Frame
6 weeks
Title
Symptom Assessment
Description
Incontinence Impact Questionnaire (IIQ-7), was used for symptomatic evaluation and to assess the impact of symptoms on quality of life. It is a validated questionnaire. A lesser score means a better outcome. Meaningful for patients. It is standardized. The patient's daily activities are taken into account. Subjective. Subject to variability. Not correlated with the severity of urine leakage.
Time Frame
6 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients with a diagnosis of OAB and unresponsive to first-line treatment, Absence of genito-urinary system malformations that may cause pollacullaire, Volunteering to participate in the research, To be literate in Turkish Exclusion Criteria: Having a urinary tract infection, Having pelvic organ prolapse greater than stage 2, To be diagnosed with stress type urinary incontinence, Having narrow-angle glaucoma, myasthenia gravis and severe gastro-intestinal diseases, Patients undergoing hemodialysis, Having severe liver or kidney failure, Pregnancy, Having a pacemaker Presence of epilepsy, The presence of built-in metal in the ankle Open ankle wound
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmet Ozgur OY Yeniel
Organizational Affiliation
Ege University School of Medicine, Department of Obstetrics and Gynecology,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ege University, School of Medicine, Department of Obstetrics and Gynecology
City
İzmir
ZIP/Postal Code
35100
Country
Turkey

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder

We'll reach out to this number within 24 hrs